Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
- 30 April 2003
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 30 (2) , 121-126
- https://doi.org/10.1053/sonc.2003.50039
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)Blood, 2001
- Fludarabine therapy in Waldenström's macroglobulinemiaAnnals of Hematology, 2000
- Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucilBritish Journal of Haematology, 2000
- Multicenter Phase II Study of Fludarabine Phosphate for Patients With Newly Diagnosed Lymphoplasmacytoid Lymphoma, Waldenström's Macroglobulinemia, and Mantle-Cell LymphomaJournal of Clinical Oncology, 1999
- Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.Journal of Clinical Oncology, 1998
- Fludarabine treatment in resistant Waldenstrom's macroglobulinemiaEuropean Journal of Haematology, 1995
- Fludarabine is an Effective Agent in Immunocytic LymphomaOncology Research and Treatment, 1994
- Fludarabine therapy in Waldenström's macroglobulinemiaThe American Journal of Medicine, 1993
- Fludarabine therapy in macroglobulinemic lymphomaBlood, 1990
- Waldenstrom's macroglobulinaemia treated with cylophosphamide and chlorambucilJournal of Clinical Pathology, 1966